Novel drug-eluting stents in the treatment of de novo coronary lesions

Vascular Health and Risk Management

Volumn 7, Issue 1, 2011, Pages 103-118

  Capodanno, Davide ^a,b   Dipasqua, Fabio ^a   Tamburino, Corrado ^a,b  

^a UNIVERSITY OF CATANIA   (Italy)

^b ETNA Foundation   (Italy)

Author keywords

Coronary artery disease; Drug; Follow up; Late lumen loss; Outcomes; Percutaneous coronary intervention; Platform; Polymer; Stent

Indexed keywords

METAL; POLYMER;

BIODEGRADABLE IMPLANT; CORONARY ARTERY DISEASE; DRUG ELUTING STENT; EVIDENCE BASED MEDICINE; HUMAN; INSTRUMENTATION; PROSTHESIS; REVIEW; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ABSORBABLE IMPLANTS; ANGIOPLASTY, BALLOON, CORONARY; CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; EVIDENCE-BASED MEDICINE; HUMANS; METALS; POLYMERS; PROSTHESIS DESIGN; TREATMENT OUTCOME;

EID: 79958259482     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S11444     Document Type: Review

References (107)

1. Hoffmann R, Mintz GS, Dussaillant GR, et al. Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation. 1996;94(6):1247-1254.
2. Sousa JE, Costa MA, Abizaid AC, et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation. 2001; 104(17):2007-2011.
3. Htay T, Liu MW. Drug-eluting stent: a review and update. Vasc Health Risk Manag. 2005;1(4):263-276.
4. Morice MC, Colombo A, Meier B, et al; REALITY Trial Investigators. Sirolimus-vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. JAMA. 2006;295(8): 895-904.
5. Millauer N, Jüni P, Hofmann A, et al. Sirolimus versus paclitaxel coronary stents in clinical practice. Catheter Cardiovasc Interv. 2011; 77(1):5-12.
6. Abizaid A. Sirolimus-eluting coronary stents: a review. Vasc Health Risk Manag. 2007;3(2):191-201.
7. Uyan C, Arinc H, Gunduz H, Akdemir R. Immediate and six months clinical and angiographic results of intracoronary paclitaxel-coated stent implantation-the Meo:DrugStar-1 study. Vasc Health Risk Manag. 2008;4(1):173-176.
8. Kirchner RM, Abbott JD. Update on the everolimus-eluting coronary stent system: results and implications from the SPIRIT clinical trial program. Vasc Health Risk Manag. 2009;5:1089-1097.
9. Sheiban I, Villata G, Bollati M, Sillano D, Lotrionte M, Biondi-Zoccai G. Next-generation drug-eluting stents in coronary artery disease: focus on everolimus-eluting stent (Xience V). Vasc Health Risk Manag. 2008; 4(1):31-38.
10. Virmani R, Guagliumi G, Farb A, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation. 2004;109(6):701-705.
11. Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation. 2007;115(11):1440-1455; discussion 1455.
12. Togni M, Windecker S, Cocchia R, et al. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J Am Coll Cardiol. 2005;46(2):231-236.
13. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48(1):193-202.
14. Kereiakes DJ, Cannon LA, Feldman RL, et al. Clinical and angiographic outcomes after treatment of de novo coronary stenoses with a novel platinum chromium thin-strut stent: primary results of the PERSEUS (Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the TAXU S Element Paclitaxel-Eluting Coronary Stent System) trial. J Am Coll Cardiol. 2010;56(4):264-271.
15. Chieffo A, Aranzulla TC, Colombo A. Drug eluting stents: focus on Cypher sirolimus-eluting coronary stents in the treatment of patients with bifurcation lesions. Vasc Health Risk Manag. 2007;3(4): 441-451.
16. Lefèvre T, Ormiston J, Guagliumi G, et al. The Frontier stent registry: safety and feasibility of a novel dedicated stent for the treatment of bifurcation coronary artery lesions. J Am Coll Cardiol. 2005;46(4): 592-598.
17. Ikeno F, Kim YH, Luna J, et al. Acute and long-term outcomes of the novel side access (SLK-View) stent for bifurcation coronary lesions: a multicenter non-randomized feasibility study. Catheter Cardiovasc Interv. 2006;67(2):198-206.
18. Ormiston J, Webster M, El-Jack S, McNab D, Plaumann SS. The AST petal dedicated bifurcation stent: first-in-human experience. Catheter Cardiovasc Interv. 2007;70(3):335-340.
19. Doi H, Maehara A, Mintz GS, Dani L, Leon MB, Grube E. Serial intravascular ultrasound analysis of bifurcation lesions treated using the novel self-expanding sideguard side branch stent. Am J Cardiol. 2009;104(9):1216-1221.
20. Grube E. Bifurcation and left main dedicated stents. Proceedings of TCT; 2009 Sep 21-25; San Francisco.
21. Albiero R. Invatec twin-rail stent: design features and clinical updates. Proceedings of TCT; 2008 Oct 12-17; Washington.
22. Van Geuns RJ. The Minvasys Nile paclitaxel-eluting sidebranch access stent: results from the BiPAX study. Proceedings of TCT; 2009 Sep 21-25; San Francisco.
23. Onuma Y, Müller R, Ramcharitar S, et al. Tryton I, First-In-Man (FIM) study: six month clinical and angiographic outcome, analysis with new quantitative coronary angiography dedicated for bifurcation lesions. EuroIntervention. 2008;3(5):546-552.
24. Ischinger TA. New devices for complex vascular interventions. The Y-Med catheter technology. Proceedings of Euro PCR; 2006 May 16-19; Paris, France.
25. Hermiller JB. The TriReme Medical Antares sidebranch access stent: design specifications and clinical trial results. Proceedings of TCT; 2009 Sep 21-25; San Francisco.
26. Sheiban I, Omedé P, Biondi-Zoccai G, Moretti C, Sciuto F, Trevi GP. Update on dedicated bifurcation stents. J Interv Cardiol. 2009;22(2): 150-155.
27. Grube E, Buellesfeld L, Neumann FJ, et al. Six-month clinical and angiographic results of a dedicated drug-eluting stent for the treatment of coronary bifurcation narrowings. Am J Cardiol. 2007;99(12): 1691-1697.
28. Verheye S, Agostoni P, Dubois CL, et al. 9-month clinical, angiographic, and intravascular ultrasound results of a prospective evaluation of the Axxess self-expanding biolimus A9-eluting stent in coronary bifurcation lesions: the DIVERGE (Drug-Eluting Stent Intervention for Treating Side Branches Effectively) study. J Am Coll Cardiol. 2009;53(12): 1031-1039.
29. Ormiston JA, Lefèvre T, Grube E, Allocco DJ, Dawkins KD. First human use of the TAXU S Petal paclitaxel-eluting bifurcation stent. EuroIntervention. 2010;6(1):46-53.
30. Van Geuns RJ. The Minvasys Nile paclitaxel-eluting sidebranch access stent: design specifications and clinical trial results. Proceedings of TCT; 2009 Sep 21-25; San Francisco.
31. Costa RA. BIPAX bifurcation study: first results. Proceedings of Euro PCR; 2010 May 25-28; Paris, France.
32. Verheye S, Grube E, Ramcharitar S, et al. First-in-man (FIM) study of the Stentys bifurcation stent-30 days results. EuroIntervention. 2009;4(5):566-571.
33. Verheye S. Latest results of the STENTYS clinical programme. Proceedings of Euro PCR; 2010 May 25-28; Paris, France.
34. Van Geuns RJ. APPOSITION II study results. Proceedings of TCT; 2010 Sep 21-25; Washington.
35. Rathore S. Small coronary vessel angioplasty: outcomes and technical considerations. Vasc Health Risk Manag. 2010;6:915-922.
36. Tanimoto S, Daemen J, Serruys PW. Update on stents: recent studies on the TAXUS stent system in small vessels. Vasc Health Risk Manag. 2007;3(4):481-490.
37. Abizaid AC, de Ribamar Costa Junior J, Whitbourn RJ, Chang JC. The CardioMind coronary stent delivery system: stent delivery on a 0.014″guidewire platform. EuroIntervention. 2007;3(1):154-157.
38. Whitbourn RJ. The CARDIOMIND stent-on-a-wire self-expanding micro-stent: results from CARE I (two year follow-up) and introduction to CARE II (sirolimus-eluting micro-stent). Proceedings of TCT; 2008 Oct 12-17; Washington.
39. Botelho R. The Cardiomind Sparrow DES program (CARE II): a bioabsorbable polymer sirolimus-eluting 'micro-stent'. Proceedings of TCT; 2009 Sep 21-25; San Francisco.
40. Abizaid AC, et al. CARE II 8 month follow-up results with the CardioMind 0.014″Sparrow sirolimus-eluting nitinol stent system. J Am Coll Cardiol. 2010;56:B53.
41. Meredith IT, Worthley S, Whitbourn R, et al; RESOLUTE Investigators. Clinical and angiographic results with the next-generation resolute stent system: a prospective, multicenter, first-in-human trial. JACC Cardiovasc Interv. 2009;2(10):977-985.
42. Udipi K, Melder RJ, Chen M, et al. The next generation Endeavor Resolute Stent: role of the BioLinx Polymer System. EuroIntervention. 2007;3(1):137-139.
43. Meredith IT, Worthley SG, Whitbourn R, et al. Long-term clinical outcomes with the next-generation Resolute Stent System: a report of the two-year follow-up from the RESOLUTE clinical trial. EuroIntervention. 2010;5(6):692-697.
44. Silber S. RESOLUTE: new insights from resolute all-comers. Proceedings of TCT; 2010 Sep 21-25; Washington.
45. Dani S, Kukreja N, Parikh P, et al. Biodegradable-polymer-based, sirolimus-eluting Supralimus stent: 6-month angiographic and 30-month clinical follow-up results from the series I prospective study. EuroIntervention. 2008;4(1):59-63.
46. Costa J. Supralimus bioabsorbable-polymer sirolimus-eluting stent technology in patients with acute coronary syndrome undergoing percutaneous coronary intervention: initial results of the prospective, international, multicenter, E-SERIES registry. Proceedings of TCT; 2009 Sep 21-25; San Francisco.
47. Han Y, Jing Q, Xu B, et al; CREATE (Multi-Center Registry of Excel Biodegradable Polymer Drug-Eluting Stents) Investigators. Safety and efficacy of biodegradable polymer-coated sirolimus-eluting stents in 'real-world' practice: 18-month clinical and 9-month angiographic outcomes. JACC Cardiovasc Interv. 2009;2(4):303-309.
48. Falotico R, Parker T, Grishaber R, Price S, Cohen SA, Rogers C. NEVO(tm): a new generation of sirolimus-eluting coronary stent. EuroIntervention. 2009;5 Suppl F:F88-F93.
49. Spaulding C, Ormiston JA, Abizaid A; on behalf of the NEVO RES-I Investigators. 6 Months results of the NEVO RES-ELUTION I (RES-I) trial. A randomized, multi-center, single-blind comparison of the NEVO(tm) sirolimus-eluting coronary stent versus the TAXU S(tm) Liberté paclitaxel-eluting coronary stent system in de novo native coronary artery lesions. Proceedings of Euro PCR; 2009 May 19-22; Barcelona, Spain.
50. Mauri L; on behalf of NEVO RES-I Investigators. NEVO RES-elution trial-12-month results and pivotal trial overview. Proceedings of TCT; 2010 Sep 21-25; Washington.
51. Vranckx P, Serruys PW, Gambhir S, et al. Biodegradable-polymerbased, paclitaxel-eluting infinnium stent: 9-month clinical and angiographic follow-up results from the SIMPLE II prospective multi-centre registry study. EuroIntervention. 2006;2(3):310-317.
52. Lemos PA, Moulin B, Perin MA, et al; PAINT Trial Investigators. Randomized evaluation of two drug-eluting stents with identical metallic platform and biodegradable polymer but different agents (paclitaxel or sirolimus) compared against bare stents: 1-year results of the PAINT trial. Catheter Cardiovasc Interv. 2009;74(5):665-673.
53. Guagliumi G, Valsecchi O, Aprile A, et al. JACTAX paclitaxel-eluting stent program. Ultra-thin abluminal PLA polymer. Focus on the randomized OCTDESI strut coverage evaluation. Proceedings of TCT; 2009 Sep 21-25; San Francisco.
54. Guagliumi G, Sirbu V, Musumeci G, et al. Strut coverage and vessel wall response to a new-generation paclitaxel-eluting stent with an ultrathin biodegradable abluminal polymer: Optical Coherence Tomography Drug-Eluting Stent Investigation (OCTDESI). Circ Cardiovasc Interv. 2010;3(4):367-375.
55. Turco MA, Ormiston JA, Popma JJ, et al. Polymer-based, paclitaxeleluting TAXUS Liberté stent in de novo lesions: the pivotal TAXUS ATLAS trial. J Am Coll Cardiol. 2007;49(16):1676-1683.
56. Grube E, Schofer J, Hauptmann KE, et al. A novel paclitaxel-eluting stent with an ultrathin abluminal biodegradable polymer 9-month outcomes with the JACTAX HD stent. JACC Cardiovasc Interv. 2010; 3(4):431-438.
57. Serruys PW, Sianos G, Abizaid A, et al. The effect of variable dose and release kinetics on neointimal hyperplasia using a novel paclitaxeleluting stent platform: the Paclitaxel In-Stent Controlled Elution Study (PISCES). J Am Coll Cardiol. 2005;46(2):253-260.
58. Kaul U, Gupta RK, Mathur A, et al. Cobalt chromium stent with antiproliferative for restenosis trial in India (COSTAR I). Indian Heart J. 2007;59(2):165-172.
59. Dawkins KD, Verheye S, Schühlen H, et al. The European cobalt STent with Antiproliferative for Restenosis trial (EuroSTAR): 12 month results. EuroIntervention. 2007;3(1):82-88.
60. Krucoff MW, Kereiakes DJ, Petersen JL, et al; COSTAR II Investigators Group. A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study. J Am Coll Cardiol. 2008;51(16): 1543-1552.
61. Wessely R, Hausleiter J, Michaelis C, et al. Inhibition of neointima formation by a novel drug-eluting stent system that allows for doseadjustable, multiple, and on-site stent coating. Arterioscler Thromb Vasc Biol. 2005;25(4):748-753.
62. Hausleiter J, Kastrati A, Wessely R, et al; Investigators of the Individualizable Drug-Eluting Stent System to Abrogate Restenosis Project. Prevention of restenosis by a novel drug-eluting stent system with a dose-adjustable, polymer-free, on-site stent coating. Eur Heart J. 2005;26(15):1475-1481.
63. Mehilli J, Kastrati A, Wessely R, et al; Intracoronary Stenting and Angiographic Restenosis-Test Equivalence Between 2 Drug-Eluting Stents (ISAR-TEST) Trial Investigators. Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss. Circulation. 2006;113(2):273-279.
64. Fitzgerald P. Commentary: ISAR test 3. Proceedings of TCT; 2008 Oct 12-17; Washington.
65. Ruef J, Storger H, Schwarz F, Haase J. Comparison of a polymer-free rapamycin-eluting stent (YUKON) with a polymer-based paclitaxeleluting stent (TAXUS) in real-world coronary artery lesions. Catheter Cardiovasc Interv. 2008;71(3):333-339.
66. Byrne RA, Iijima R, Mehilli J, et al. Durability of antirestenotic efficacy in drug-eluting stents with and without permanent polymer. JACC Cardiovasc Interv. 2009;2(4):291-299.
67. Grube E. BIOFREEDOM: a prospective randomized trial of polymerfree biolimus a9-eluting stents and paclitaxel-eluting stents in patients with coronary artery disease. Proceedings of TCT; 2009 Sep 21-25; San Francisco.
68. Tada N, Virmani R, Grant G, et al. Polymer-free biolimus a9-coated stent demonstrates more sustained intimal inhibition, improved healing, and reduced inflammation compared with a polymer-coated sirolimuseluting cypher stent in a porcine model. Circ Cardiovasc Interv. 2010; 3(2):174-183.
69. Fajadet J. The Minvasys Amazonia PAX and Nile PAX polymer free paclitaxel eluting stent program. Proceedings of TCT; 2009 Sep 21-25; San Francisco.
70. Abizaid A. PAX A trial: 4-months follow-up results. Proceedings of Euro PCR; 2010 May 25-28; Paris, France.
71. Costa JR Jr, Abizaid A, Costa R, et al. 1-year results of the hydroxyapatite polymer-free sirolimus-eluting stent for the treatment of single de novo coronary lesions: the VESTASYNC I trial. JACC Cardiovasc Interv. 2009;2(5):422-427.
72. Abizaid A. VESTAsync I update, and First Report of the VESTAsync II randomized trial with a hydroxyapatite polymer-free sirolimus-eluting stent. Proceedings of TCT; 2009 Sep 21-25; San Francisco.
73. Verheye S, Agostoni P, Dawkins KD, et al. The GENESIS (Randomized, Multicenter Study of the Pimecrolimus-Eluting and Pimecrolimus/ Paclitaxel-Eluting Coronary Stent System in Patients with De Novo Lesions of the Native Coronary Arteries) trial. JACC Cardiovasc Interv. 2009;2(3):205-214.
74. Costa JR Jr, Abizaid A, Feres F, et al. EXCELLA First-in-Man (FIM) study: safety and efficacy of novolimus-eluting stent in de novo coronary lesions. EuroIntervention. 2008;4(1):53-58.
75. Serruys PW, Garg S, Abizaid A, et al. A randomised comparison of novolimus-eluting and zotarolimus-eluting coronary stents: 9-month follow-up results of the EXCELLA II study. EuroIntervention. 2010; 6(2):195-205.
76. Garg S, Sarno G, Serruys PW, et al. The twelve-month outcomes of a biolimus eluting stent with a biodegradable polymer compared with a sirolimus eluting stent with a durable polymer. EuroIntervention. 2010; 6(2):233-239.
77. Klauss V. LEADERS: two-year follow-up from a prospective randomized trial of biolimus A9-eluting stents with a bioabsorbable polymer vs. sirolimus-eluting stents with a durable polymer. Proceedings of TCT; 2009 Sep 21-25; San Francisco.
78. Esteves V, Abizaid A, Centemero MP, et al. Five-year clinical results of the biolimus A9 eluting stent with biodegradable polymer. Proceedings of Euro PCR; 2010 May 25-28; Paris, France.
79. Ostojic M, Sagic D, Beleslin B, et al. First clinical comparison of Nobori-Biolimus A9 eluting stents with Cypher-Sirolimus eluting stents: Nobori Core nine months angiographic and one year clinical outcomes. EuroIntervention. 2008;3(5):574-579.
80. Chevalier B, Silber S, Park SJ, et al; NOBORI 1 Clinical Investigators. Randomized comparison of the Nobori Biolimus A9-eluting coronary stent with the Taxus Liberté paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the NOBORI 1 trial-Phase 2. Circ Cardiovasc Interv. 2009;2(3):188-195.
81. Hamilos MI, Ostojic M, Beleslin B, et al; NOBORI CORE Investigators. Differential effects of drug-eluting stents on local endothelium-dependent coronary vasomotion. J Am Coll Cardiol. 2008;51(22): 2123-2129.
82. Rutsch W, Witzenbichler B, Schuhlen H. Multicentre first-in-man study with the lowest known limus dose on the Elixir medical myolimus(tm) eluting coronary stent system with a durable polymer: 12-month clinical and six month angiographic and IVUS follow-up. Proceedings of Euro PCR; 2009 May 19-22; Barcelona, Spain.
83. Schoefer J, Dudek D, Witzenbichler B, et al. Multicenter, first-in-man study on the Elixir Myolimus-eluting coronary stent system with bioabsorbable polymer: 12-month clinical and angiographic/IVUS results. Proceedings of Euro PCR; 2010 May 25-28; Paris, France.
84. Wykrzykowska JJ, Onuma Y, Serruys PW. Advances in stent drug delivery: the future is in bioabsorbable stents. Expert Opin Drug Deliv. 2009;6(2):113-126.
85. Ormiston JA, Serruys PW. Bioabsorbable coronary stents. Circ Cardiovasc Interv. 2009;2(3):255-260.
86. Ormiston JA, Serruys PW, Regar E, et al. A bioabsorbable everolimuseluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet. 2008; 371(9616):899-907.
87. Serruys PW, Ormiston JA, Onuma Y, et al. A bioabsorbable everolimuseluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet. 2009;373(9667):897-910.
88. Ormiston JA. BVS cohort A: four year results and lessons learned. Proceedings of TCT; 2010 Sep 21-25; Washington.
89. Tanimoto S, Serruys PW, Thuesen L, et al. Comparison of in vivo acute stent recoil between the bioabsorbable everolimus-eluting coronary stent and the everolimus-eluting cobalt chromium coronary stent: insights from the ABSORB and SPIRIT trials. Catheter Cardiovasc Interv. 2007;70(4):515-523.
90. García-García HM, Gonzalo N, Pawar R, et al. Assessment of the absorption process following bioabsorbable everolimus-eluting stent implantation: temporal changes in strain values and tissue composition using intravascular ultrasound radiofrequency data analysis. A substudy of the ABSORB clinical trial. EuroIntervention. 2009;4(4): 443-448.
91. Sarno G, Onuma Y, Garcia Garcia HM, et al. IVUS radiofrequency analysis in the evaluation of the polymeric struts of the bioabsorbable everolimus-eluting device during the bioabsorption process. Catheter Cardiovasc Interv. 2010;75(6):914-918.
92. Okamura T, Garg S, Gutiérrez-Chico JL, et al. In vivo evaluation of stent strut distribution patterns in the bioabsorbable everolimus-eluting device: an OCT ad hoc analysis of the revision 1.0 and revision 1.1 stent design in the ABSORB clinical trial. EuroIntervention. 2010;5(8): 932-938.
93. Serruys PW. BVS cohort B: device design, 6-month update, and first report of the 12-month results. Proceedings of TCT; 2010 Sep 21-25; Washington.
94. Kaluza GL. Current status of polymeric biodegradable drug eluting stents II: REVA Medical, Inc. Proceedings of TCT; 2006 Oct 22-27; Washington.
95. Grube E. The REVA tyrosine-derived polycarbonate bioabsorbable stent: final results from the RESORB first-in-man clinical trial and next generation designs. Proceedings of TCT; 2008 Oct 12-17; Washington.
96. Pollman MJ. Engineering a bioresorbable stent: REVA programme update. EuroIntervention. 2009;5 Suppl F:F54-F57.
97. Abizaid A. The REVA tyrosine-derived polycarbonate bioabsorbable stent: lessons learned and future directions. Proceedings of TCT; 2009 Sep 21-25; San Francisco.
98. Jabara R, Pendyala L, Geva S, Chen J, Chronos N, Robinson K. Novel fully bioabsorbale salicylate-based sirolimuseluting stent. EuroIntervention. 2009;5 Suppl F:F58-F64.
99. Abizaid A. The BTI salycilate-based polyanhydride ester absorbable sirolimus-eluting stent: update from the Whisper study. Proceedings of TCT; 2008 Oct 12-17; Washington.
100. Jabara R. Poly-anhydride based on salicylic acid and adipic acid anhydride. Proceedings of Euro PCR; 2009 May 19-22; Barcelona, Spain.
101. Tamai H, Igaki K, Kyo E, et al. Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation. 2000;102(4):399-404.
102. Nishio S, et al. Long-term (.10 years) clinical outcomes of firstin-man biodegradable poly-l-lactic acid coronary stents. Proceedings of Euro PCR; 2010 May 25-28; Paris, France.
103. Onuma Y, Garg S, Okamura T, et al. Ten-year follow-up of the IGAKI-TAMAI stent. A posthumous tribute to the scientif ic work of Dr. Hideo Tamai. EuroIntervention. 2009;5 Suppl F:F109-F111.
104. Vogt F, Stein A, Rettemeier G, et al. Long-term assessment of a novel biodegradable paclitaxel-eluting coronary polylactide stent. Eur Heart J. 2004;25(15):1330-1340.
105. Heublein B, Rohde R, Kaese V, Niemeyer M, Hartung W, Haverich A. Biocorrosion of magnesium alloys: a new principle in cardiovascular implant technology? Heart. 2003;89(6):651-656.
106. Erbel R, Di Mario C, Bartunek J, et al; PROGRESS-AMS (Clinical Performance and Angiographic Results of Coronary Stenting with Absorbable Metal Stents) Investigators. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. Lancet. 2007;369(9576): 1869-1875.
107. Waksman R. Current state of the absorbable metallic (magnesium) stent. EuroIntervention. 2009;5 Suppl F:F94-F98.